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Abstract
Background:  The  objective  was  to study  targeted  therapies  using  a  biologically
active monoclonal antibody against intracellular adhesion molecule-1 (ICAM-1 mAb)
and an siRNA targeting thyroid-stimulating hormone (TSH) receptor (TSHR) in a
BALB/c mouse model of Graves’ disease (GD).
Material and methods: An improved method for establishing a stable model of GD
in BALB/c mice was developed by immunization with pcDNA 3.1/TSHR 289 and
electroporation  (EP).  The  mice  in  which  GD  was  successfully  established  were
divided  into  a  nontreated  control  group,  which  was  treated  with  continuous
immunization, and treated groups, which were treated with the siRNA and ICAM-1
mAb.  Normal  mice  were  included  as  a  blank  group.  These  groups  were  used  to
compare the effects of treatment with the ICAM-1 mAb and siRNA.
Results: The two novel treatments markedly improved weight loss, serum thyroxine
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(T4) levels, thyroid-stimulating hormone antibody (TSAb) levels, thyroid-stimulating
blocking antibody (TSBAb) levels and thyroid uptake of 99mTcO4  in GD model mice.
Compared  with  the siRNA treatment,  treatment  with  the  ICAM-1  mAb produced
more obvious benefits. The differences in the posttreatment indexes between the two
treatment groups were statistically significant (p < 0.05).
Conclusions: These preliminary data suggest that both the biologically active ICAM-
1 mAb and the siRNA targeting TSHR were effective. The ICAM-1 mAb exerted a
better  therapeutic  effect  than the siRNA targeting TSHR. Both treatments  showed
potential efficacy as novel treatments for GD and may therefore represent therapeutic
options in addition to the existing drugs or interventions.
Key words:  Graves’ disease; Graves’ ophthalmopathy; TSHR; siRNA; monoclonal
antibody; ICAM-1
Introduction
Graves’ disease  (GD)  is  an  autoimmune  thyroid  disorder  that  is  caused  by
antibodies directed against the TSH receptor (TSHR), leading to hyperthyroidism, and
a genetically predisposed autoimmune disease. Typical characteristics of GD include
metabolic syndrome, goiter and Graves’ orbitopathy (GO). The condition is generally
mediated by autoantibodies but also involves subsets of immune cells [1].
Currently,  three main treatment  methods for GD are used in clinical  practice:
antithyroid drugs (ATDs), radioactive iodine (RAI) therapy and surgical treatment.
However,  ATD  treatment  is  characterized  by  relatively  high  relapse  rates  and
concerning  side  effect  profiles,  and  the  other  two  treatments  may  cause
hypothyroidism  [2].  The  current  treatment  options  for  GD  are  also  suboptimal
because they target the signs and symptoms of the disease rather than the pathogenic
mechanisms. If left untreated, GD leads to significant morbidity and mortality [3].
TSHR is currently the main focus of research on the etiology and pathogenesis of
GD, and TSHR is an important independent risk factor in the pathogenesis of GD [4].
Many scholars [5–7] postulate that the thyrotropin receptor antibody (TRAb), a self-
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reactive antibody against  TSHR, binds to TSHR on the thyroid cell  membrane to
cause  thyroid  cell  stimulation,  excessive  growth  and  thyroid  hormone  synthesis.
Increased  hormone  secretion  leads  to  thyrotoxicosis  [8].  The  duration  of  ATD
treatment  is  affected  by  the  titer  of  TRAb [9].  Intercellular  adhesion  molecule-1
(ICAM-1) is a member of the immunoglobulin superfamily that is expressed on the
plasma membrane of antigen-presenting cells. ICAM-1 plays an important role in the
development of autoimmune thyroid disease and GO [10, 11]. The level of soluble
ICAM-1 in the serum is related to GO activity and severity and can be used as an
indicator for the GO diagnosis, staging, disease monitoring and treatment efficacy
evaluations  [12]. In our paper, the treatment strategies used to treat GD model mice
included a biologically active ICAM-1 mAb and an siRNA targeting TSHR, which
directly act on ICAM-1 and TSHR, respectively.
Material and methods
Establishment of the GD mouse model
A total of female BALB/c mice were purchased from the Institute of Laboratory
Animal Sciences, Chinese Academy of Medical Sciences (Beijing, China). They were
all 6 to 8 weeks old and weighed 18 to 20 g. All animals were housed with free access
to laboratory food and water  on a 12/12 h light/dark cycle.  They were housed in
groups of 5 animals per cage at a constant temperature (18–20°C) and humidity (65–
69%). pcDNA 3.1/TSHR 289 was prepared and preserved in our laboratory. All 70
female  BALB/c mice were  injected with  pcDNA 3.1/TSHR 289 into the  bilateral
gastrocnemius  and  electroporated  (EP)  every  3  weeks  4  times.  The  protocol  for
establishing the GD mouse model was described in our previous article [13]. This
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Nthy-ori-3-1  normal  human  thyroid  cells  (No.  c1002)  were  purchased  from
Huiying Biological Technology Co., Ltd. (Shanghai, China). The cells were cultured
in a cell  incubator at  37°C with 5% CO2.  According to the TSHR gene sequence
published  by GenBank  (Rat  GI  6981679,  Mouse  GI  575923),  two  siRNAs  were
designed and synthetized in accordance with the homologous gene sequence of TSHR
in Nthy-ori-3-1 normal human thyroid cells and BALB/c mice using Ambion’s online
design  software.  The  siRNA  sequences  were  as  follows:  siRNA  1012:  sense
ACAAAACUCCAAGUUCCAGtt, antisense CUGGAACUUGGAGUUUUGUtt; and
siRNA  1041:  sense  GCAACUCUCACUAUUACGUtt,  antisense
ACGUAAUAGUGAGAGUUGCtt.  Designed  siRNAs  were  purchased  from  Bao
Biotechnology Co., Ltd. (Dalian, China). Nthy-ori-3-1 cells were cultured with RPMI
1640 medium in an incubator, and synthetic siRNA was transfected into Nthy-ori-3-1
cells.  Cellular  proteins  were  extracted  after  transfection.  The  difference  in  the
expression levels of TSHR before and after transfection was detected using Western
blotting.
Preparation of the ICAM-1 mAb
ICAM-1  mAbs  were  prepared  and  preserved  in  our  laboratory.  We  used  pure
ICAM-1 protein to immunize BALB/c mice, removed the spleen, and fused the cells
with myeloma cells  (SP2/0).  We selected the secretion wells,  subcloned them and
prepared mAbs in quantity using the induction method in vivo. Then, we acquired the
ICAM-1 mAb from purified ascites. The protocol for preparing the ICAM-1 mAb was
published in our previous article [14].
Animal grouping and treatment plan
At week 12, which was the end of the immunization period, 53 of the 70 mice
presented increased levels of T4, TSAb and TSBAb. The rate of immunization success
was therefore 75.71%. Fifty mice in which GD was successfully established were
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randomly assigned to five groups (groups A–E). In addition, age-matched mice that
were unimmunized and untreated were used as a control for comparisons (group F).
Each group included 10 mice.
The  study  protocol  included  four  immunizations  every  3  weeks  (groups  A-E),
followed by a  ‘maintenance’ phase that  included additional  regular  immunizations
every 3 weeks until the end of the experiment (groups A, C, and E). The siRNA (10
µg/piece) was administered to groups A and B via intraperitoneal (i.p.) injection 3
times 2 weeks after the fourth immunization (week 12), with 2 days between each
injection. The ICAM-1 mAb (10 µg/injection) was administered to groups C and D
using the same method as the siRNA was administered to groups A and B. The siRNA
and ICAM1 mAb were dissolved in 0.9% NaCl without further additives. A detailed
treatment schedule is shown in Figure 1. A detailed explanation of the animal groups
is shown in Table 1.
Serum indicator measurements
Total serum T4 levels were measured in blood collected from the angular vein using
radioimmunoassay  and  immunoradiometric  kits  (Beijing  North  Institute  of
Biotechnology, Beijing, China) at 2 weeks after each immunization and at the end of
the experiment. TSAb and TSBAb levels were measured in blood collected from the
angular vein using ELISAs  at  the same time points described above. Two ELISA
methods for the detection of TSAb and TSBAb have been established and evaluated
by our laboratory [15].
99mTcO4- radioactive isotope imaging
 The mouse images were obtained by using a small animal single-photon emission
computer  tomography  (SPECT)  machine  (NanoSCAN;  Mediso,  Hungary).
Pertechnetate (99mTcO4-) was produced by a molybdenum technetium generator (China
Institute  of  Atomic  Energy,  Beijing,  China).  Whole-body  99mTcO4 imaging  was
performed at week 12 (2 weeks after the fourth immunization) and week 18 (the end
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of the experiment). Each mouse was anesthetized with 3% isoflurane, followed by an
intraperitoneal injection of 37 MBq 99mTcO4- (1 mCi/0.1 mL) while the mouse was in a
prone  position.  The  scintillation  scan  was  performed  10  min  later  using  the
NanoSCAN small animal SPECT/CT with a multipinhole collimator, peak energy of
140 keV, and total acquisition time of only 2 h.
Weight, morphological and pathological analyses
A total of mice were weighed 2 weeks after each immunization and at  the end of
the  experiment.  The  mice  were  subsequently  sacrificed  by  cervical  vertebra
dislocation at the end of the experiment. The thyroid gland, eyeball and heart were
removed and fixed with 10% formalin. One week later, the tissues were embedded in
paraffin blocks, sectioned and stained with hematoxylin and eosin (HE) for analysis,
and pathological changes were observed.
Statistical analysis
SPSS software version 25.0 (IBM SPSS, Armonk, NY, USA) was used to analyze
the data. The data from each group are presented as the means±standard deviations.
The t test was used to compare means between two groups, and the LSD method with
one-way  analysis  of  variance  (one-way  ANOVA)  was  used  to  compare  means
between multiple groups. p < 0.05 was considered to indicate statistical significance.
Results
TSHR expression after siRNA transfection
Twenty-four hours after the siRNA transfection, the expression level of TSHR in
the Nthy-ori-3-1 cells was significantly downregulated (shown in Fig. 2).
Determination of serum T4 levels
The T4 levels did not differ between experimental mice before immunization (week
0), and the average levels of T4 increased slowly.  After initiating therapy, the two
treatment  groups showed progressively decreasing T4 levels.  Among the sustained
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immunization groups, the T4 levels in the siRNA group (group A) decreased from
65.71 ± 6.89 ng/mL to 27.58 ± 1.94 ng/mL, and those in the ICAM-1 mAb group
(group C) decreased from 70.84 ± 8.46 ng/mL to 27.24 ± 3.50 ng/mL. Among the
groups without sustained immunization, the T4 levels in the siRNA group (group B)
decreased from 68.23 ± 6.38 ng/mL to 22.48 ± 2.43 ng/mL, and those in the ICAM-1
monoclonal antibody group (group D) decreased from 67.45 ± 7.29 ng/mL to 16.32 ±
1.53  ng/mL  (all  p  <  0.05).  However,  the  values  mentioned  above  were  still
significantly higher than those in the unimmunized blank group (group F) (13.97 ±
1.41 ng/mL) and lower than those in the immunized group (group E) (69.03 ± 2.72
ng/mL) at the same time points before and after treatment (p < 0.05 shown in Fig. 3).
Determination of serum TSAb and TSBAb levels
The  mean  levels  of  TSAb  and  TSBAb gradually  increased  following  the  first
immunization.  The  decreases  in  the  serum  TSAb  and  TSBAb  levels  in  the  two
treatment  groups  were  compared.  Among  the  sustained  immunization  groups,  the
TSAb and TSBAb levels in the siRNA group (group A) decreased from 457.33 ±
45.85 µIU/mL to 331.44 ± 43.38 µIU/mL and from 15.83 ± 5.92 µIU/mL to 13.94 ±
1.11 µIU/mL, respectively. The levels in the ICAM-1 mAb group (group C) decreased
from 443.91 ± 42.32 µIU/mL to 275.16 ± 45.80 µIU/mL and from 17.05 ± 6.16
µIU/mL to  14.59 ±  1.02 µIU/mL,  respectively (all  p  < 0.05).  Among the  groups
without sustained immunization, the TSAb and TSBAb levels in the siRNA group
(group B) decreased from 462.07 ± 46.12 µIU/mL to 283.91 ± 25.53 µIU/mL and
from 15.22  ±  7.29  µIU/mL to  12.96  ±  1.27  µIU/mL,  respectively.  Levels  in  the
ICAM-1  monoclonal  antibody  group  (group  D)  decreased  from  483.48  ±  44.29
µIU/mL to 119.12 ± 40.53 µIU/mL and from 16.81 ± 6.05 µIU/mL to 9.56 ± 1.99
µIU/mL, respectively (all p < 0.05). However, the values mentioned above were still
significantly higher than those in the unimmunized blank group (group F) (6.37 ±
2.86 µIU/mL and 5.94 ± 3.22 µIU/mL, respectively)  and lower than those in the
immunized group (group E) (504.84 ± 42.77 µIU/mL and 17.14 ± 2.76 µIU/mL,
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respectively) at the same time points before and after treatment (p < 0.05). After each
treatment,  a  statistically  significant  decrease  in  the  TSAb and TSBAb levels  was
observed in groups A-D (all p < 0.05No significant differences in the serum TSAb and
TSBAb levels were observed in groups E and F during the course of treatment (shown
in Fig. 4).
99mTcO4- radioactive isotope imaging
Thyroid 99mTcO4- imaging was performed on each mouse (NanoSCAN small animal
SPECT/CT, shown in Fig. 5). The uptake of 99mTcO4- by the thyroid was increased in
the experimental group following the fourth immunization. After treatment, compared
with the blank group (group F), groups A-E exhibited increased 99mTcO4- uptake in the
thyroid.  99mTcO4- uptake in the thyroid of group E was higher than that of the other
groups. No significant differences in 99mTcO4- uptake were observed between the two
treatment groups.
Weight, morphological and pathological analyses
The mean weights of mice in the three groups were similar prior to the experiment.
The weights  of  mice  increased steadily during  immunization.  After  treatment,  the
weights of the mice in each treated group (groups A-D) were slightly higher than
those in group E (all p < 0.05) but still lower than those in the blank group (group F)
(all p < 0.05). A significant difference in weight gain was not observed between any
two treated groups (shown in Fig. 6).
As  shown  in  Fig.  7,  an  examination  of  the  thyroid  tissues  in  groups  A-E  via
microscopy revealed decreased thyroid follicular colloid and lymphocyte infiltration
and partial microfollicular hyperplasia. Group F lacked these pathological changes.
Optic nerve edema was observed in the partial postbulbar tissues of the mice (groups
A–E) and was most obvious in group E. Edema of the extraocular muscles of mice
was  observed  in  group  B.  Group  F  lacked  these  pathological  changes,  but  iris
papillary hyperplasia was occasionally identified. HE staining of the heart tissues of
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the  mice  in  groups  A–E  showed  endocardial  fibroblast  hyperplasia,  dilation  and
congestion of blood vessels between the myocardium, but no significant differences in
these pathological features were observed between the two treatment groups.
Discussion
Mouse models of GD allow us to better understand the disease and to investigate
novel therapeutic approaches. Over the years, many scholars at home and abroad have
tried to prepare GD animal models by using various methods, but the results have not
been satisfactory [16]. Currently, the most common method for constructing a GD
model  is  to  immunize  BALB/c  mice  with  an  adenovirus  or  plasmids  expressing
TSHR. Although this method achieves a high success rate and is easy to replicate, it
also has some problems, such as a short expression time [17, 18].  Kim-saijo [19]
attempted to establish a transgenic animal model, which transferred some TSAb gene
fragments  into  the  fertilized  eggs  of  C57BL/6J  mice.  In  the  present  study,  an
improved method was used to induce GD in BALB/c mice in which the recombinant
plasmid pcDNA3.1/TSHR289 was injected followed by electroporation (EP).  This
model features an extension of the initial phase to include a maintenance phase. This
novel  method has the advantages of a  high success rate,  short  model  cycle,  good
stability, reproducibility and no interference from self-relief in model mice after the
cessation of immunization.
GD is an autoimmune thyroid disease (AITD) characterized by hyperthyroidism,
diffuse goiter and antibodies mainly against TSHR, thyroid peroxidase (TPO) and/or
thyroglobulin (Tg) [20]. The current treatment options for GD are also suboptimal
because they target the signs and symptoms of the disease rather than the pathogenic
mechanisms.  Scholars  from  all  over  the  world  are  committed  to  finding  a  new
treatment  for  the  etiological  cause  of  GD that  will  permanently treat  this  disease
without  destroying  or  removing  the  thyroid  gland.  Some  scholars  found  that  the
presence  of  type  2  deiodinase  peptide  antibodies  is  associated  with  Graves’
hyperthyroidism, influencing the levels of antibodies against TPO, Tg and TSHR, as
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well as the therapeutic efficacy of antithyroid drugs [21]. According to Reyhane [22],
TPO expression in the endometrium and placenta may explain the higher frequency of
abortion and infertility in patients with thyroid autoimmunity. However, most of the
research focuses on the development of inhibitors of TSHR, such as antibodies, and
strategies to prevent GD by silencing genes. RNA interference (RNAi) refers to the
introduction of a double-stranded RNA of a homologous sequence to an endogenous
mRNA coding region into a cell to specifically degrade the mRNA and silence the
expression of the gene. Although RNAi represents a fast and efficient technique for
inhibiting  gene  expression,  many  scholars  have  found  that  siRNAs  that  are  not
randomly designed exert  a  gene-silencing effect.  Song [23]  designed a  6-segment
siRNA corresponding to the gene encoding the mouse apoptotic receptor Fas, but only
3 of the siRNAs achieved the expected results. Yoshinari and colleagues [24] showed
that the expected genomic silencing effect is substantially reduced when the starting
position of the siRNA sequence is shifted by 1 to 2 bases. However, siRNA therapies
are  hindered  by poor  intracellular  uptake,  limited  blood  stability  and  nonspecific
immune  stimulation.  In  addition,  the  target  cell  types  and  target  genes  must  be
identified, and the temporal and spatial effects on gene expression must be understood
to  effectively  utilize  siRNA-mediated  endogenous  gene  silencing  in  a  therapeutic
setting. In this experiment, the siRNA that was designed to inhibit the expression of
the  target  gene  TSHR and  that  exerted  the  best  effect  was  selected  for  use  as  a
treatment. The mRNA levels of the TSHR gene decreased significantly, and the levels
of the TSHR protein decreased accordingly.
ICAM-1  is  a  cell  surface  single-chain  glycoprotein  that  binds  to  lymphocyte
function-associated antigen-1 ligand and mediates cell-to-cell, cell-to-matrix or cell-
matrix-cell  adhesion;  ICAM-1  is  involved  in  antigen  recognition,  complement
fixation, and cell adhesion. ICAM-1 is also closely related to the pathogenesis of GD
[25, 26]. Some scholars have confirmed that patients with GD exhibit a large amount
of ICAM-1 expression on the surface of thyroid cells during continuous stimulation
with  autoantibodies.  A large  number  of  lymphocyte  function-associated  antigen-1
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ligands are expressed on the membranes of infiltrating T lymphocytes and monocytes,
and the ICAM-1/LFA-1 pathway mediates autoimmune damage to thyroid tissue [27].
Significant inhibition of the secretion and synthesis of soluble intercellular adhesion
molecule-1 using glucocorticoids exerts a clear effect on GD by controlling the rate of
disease development [28, 29]. Therefore, the level of sICAM-1 can be used as an
important  criterion  to  evaluate  the  severity  of  GD  and  to  choose  the  time  for
intervention. The level of sICAM-1 can also be used to predict the risk of recurrence.
Therefore, this study used the ICAM-1 monoclonal antibody previously constructed
by our laboratory to treat GD model mice and explored its therapeutic effects [14]. The
effects of the siRNA against TSHR and the ICAM-1 mAb were compared in the same
study because these two treatment methods affect the immune state: TSHR-targeted
therapy affects the cause of GD, ICAM-1-targeted therapy affects the immune state,
and sICAM-1 therapy is a supplement to TRAb that affects the immune state and
immune repair  and can  be used to  evaluate  the  probability of  disease recurrence.
Therefore,  both  agents  were studied  together  to  prepare for  subsequent  studies  of
strategies using them in combination.
After the successful treatment of mice with the siRNA and ICAM-1 monoclonal
antibodies, T4 and TSAb levels were significantly decreased and the body weights
increased.  We  showed  that  pcDNA 3.1/TSHR 289  immunization  in  mice  can  be
extended using a novel protocol, in which regular injections every 4 weeks served to
continuously increase antibody production. In summary, a long-term model of GD
induced by a relatively simple protocol of sustained immunizations should facilitate
the investigation of the mechanisms of long-term disease and may avoid the need for
more complicated disease models. However, regardless of whether the recombinant
plasmid was used for sustained immunization in the corresponding groups, serum T4
levels were significantly improved compared to those in the untreated group, but they
still did not reach normal levels. The uptake of thyroid 99mTcO4- was lower in groups
A-D than in  group E,  indicating that  both treatment  methods were effective.  The
serum T4 and TSAb levels in the ICAM-1 monoclonal antibody-treated group were
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lower than those in the siRNA-treated group, indicating that the therapeutic effect of
the ICAM-1 monoclonal antibody was somewhat better than that of the siRNA. Many
sites are present in the TSHR gene. In addition, siRNA therapies are limited by poor
intracellular  uptake,  low  blood  stability  and  nonspecific  immune  stimulation.  A
relationship  between  the  treatment  dose  and  the  duration  of  treatment  has  been
identified.  The  most  effective  treatment  dose  and  duration  still  require  further
exploration.
No  significant  difference  in  99mTcO4- uptake  was  observed  between  group  A
(continuous  immunization  +  siRNA)  and  group  C  (continuous  immunization  +
ICAM-1 mAb) or between group B (siRNA) and group D (ICAM-1 mAb). However,
the 99mTcO4- uptake in groups A-D was lower than that in group E, indicating that the
two treatments were effective, but the low dose and short duration might affect the
results  observed after  treatment.  The pathological  examination of  mice in  the late
stage  of  the  experiment  revealed  that  the  thyroid  glands  of  the  GD  model  mice
showed corresponding hyperthyroidism characteristics,  but  a  significant  difference
was  not  observed  between  the  two  treatments.  Histological  changes  are  often
associated with serological changes, but histological changes after treatment usually
occur later than serological changes. Optic nerve edema was observed in the partial
postbulbar  tissues  of  the  mice  and  was  most  obvious  in  group  E.  Edema  of  the
extraocular muscles of mice was detected in group B. We are not sure whether these
symptoms are related to the exophthalmos observed in patients with hyperthyroidism,
and  further  experimental  data  are  needed  to  explain  this  phenomenon.  Group  F
occasionally had visible iris papillary hyperplasia, but this change could have been
related to the age of the mice. HE staining of the heart tissues of the mice in groups A-
E showed endocardial  fibroblast  hyperplasia  and dilation and congestion of blood
vessels  between  the  myocardium;  fibroblast  proliferation  is  usually  related  to
thrombus. The abovementioned pathological changes may be related to heart diseases
caused  by  hyperthyroidism,  such  as  arrhythmia,  which  can  cause  thrombosis.
However,  this  study  has  limitations.  We  cannot  exclude  the  possibility  that  the
12
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effective dose was not reached due to the short duration of treatment. In addition, we
do not currently have a full explanation for the observed effects, which require further
investigation.
In summary, treatment of a mouse GD model with an siRNA and ICAM-1 mAb led
to marked improvements in several disease parameters. In our future research,  we
may extend the treatment time, use different treatment doses, increase the number of
treatments appropriately, explore the best treatment methods and therapeutic doses,
and examine the potential for future clinical treatment.
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Table 1. Animal grouping and treatment plan
Immunized Sirna ICAM-1 MAB
Group A + + -
Group B - + -
Group C + - +
Group D - - +
Group E + - -
Group F - - -
Immunized — continuous recombinant plasmid pcDNA3.1/TSHR289 injection + EP; siRNA
— intraperitoneal  injection  of  siRNA (1  dose  per  48h,  3  times  total);  ICAM-1 mAb —
intraperitoneal injection of ICAM-1 monoclonal antibody (administered once every 48 h for 3
times)
Figure 1. A detailed treatment schedule
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Figure  2.  The  expression  level  of  TSHR in  the  Nthy-ori-3-1  cells.  After  siRNA
transfection for 24 h, the expression level  of TSHR in Nthy-ori-3-1 cells  was
significantly down-regulated
Figure  3. The  levels  of  total  serum  T4 before(lowercase)  and  after(uppercase)
treatment.  As  can  be  seen,  during  continuous  immunization,  serum  T4 level
decreased in siRNA group (group A) and ICAM-1 monoclonal antibody group
(group  C).  During  non-sustained  immunization,  serum  T4 level  decreased  in
siRNA group (group B) and ICAM-1 monoclonal antibody group (group D). But
at the same time point before and after treatment in the above group the above
serum T4 level still higher than the unimmunized blank group (group F) (#p <
0.05, all p = 0.0001) and lower than the immunized group (group E) (▲p < 0.05,
all  p = 0.0001). There was a statistically significant difference in T4 levels of
group A, group B, group C and group D before and after each their treatment (*p
< 0.05, all p < 0.0001). 
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Figure  4. The  levels  of  total  serum  TSAb and  TSBAb  before  (lowercase)  and
after(uppercase)  treatment.  As  can  be  seen,  during  continuous  immunization,
serum TSAb and TSBAb level decreased in siRNA group (group A) and ICAM-1
monoclonal antibody group (group C).During non-sustained immunization, serum
TSAb  and  TSBAb  level  decreased  in  siRNA group  (group  B)  and  ICAM-1
monoclonal  antibody group (group D).But the above data still  higher than the
unimmunized blank group (group F) (#p < 0.05, all p = 0.0001) and lower than
the immunized group (group E) (▲p < 0.05, all p = 0.0001)at the same time point
before and after treatment in the above group. There was a statistically significant
difference in TSAb levels of group A, group B, group C and group D before and
after each their treatment (*p < 0.05, all p < 0.0001)
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Figure 5. Thyroid  99mTcO4-  imaging after treatment. The tracer concentration region
was observed as mouse thyroid. It can be seen that the uptake capacity of thyroid
99mTcO4- in  mice  of  group  E  is  significantly  enhanced  compared  with  other
groups. There were no significant differences in 99mTcO4- uptake between the two
treatment groups
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Figure 6. The weight of mice after treatment. It can be seen that the weight of mice in
each group after treatment was slightly higher than that in the group E (p < 0.05,
p = 0.0464,  0.0222,  0.0344,  0.0283),  but  still  lower  than the  unimmunized  F
group (p < 0.05, p = 0.0227, 0.0416, 0.0323, 0.0448). There was no significant
difference in the weight gain between the mice in each group
Figure  7. An  examination  of  the  thyroid  tissues  in  groups  A-E  via  microscopy
revealed  decreased  thyroid  follicular  colloid  and  lymphocyte  infiltration  and
partial microfollicular hyperplasia. Group F lacked these pathological changes.
Optic  nerve edema was observed in  the partial  postbulbar tissues of the mice
(groups  A–E)  and  was  most  obvious  in  group  E.  Edema  of  the  extraocular
muscles of mice was observed in group B. Group F lacked these pathological
changes, but iris papillary hyperplasia was occasionally identified. HE staining of
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the  heart  tissues  of  the  mice  in  groups  A–E  showed  endocardial  fibroblast
hyperplasia, dilation and congestion of blood vessels between the myocardium,
but  no  significant  differences  in  these  pathological  features  were  observed
between the two treatment groups
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